Surgery Websites
Transplant Surgery »  Meet the Team »  Basic Scientists »  Rajalingam Raja, Ph.D., D(ABHI)
Rajalingam Raja, Ph.D., FRCPath., D(ABHI)

Rajalingam Raja, Ph.D., FRCPath., D(ABHI)

  • Clinical Professor of Surgery
  • Director, Immunogenetics and Transplantation Laboratory

Contact Information

UCSF Immunogenetics and Transplantation Laboratory
Department of Surgery, Box 0508
3333 California Street, Suite 150
San Francisco, CA 94143
415-476-3883 Phone
415-476-0379 Fax
Open Popup

University of Madras, India. B.Sc., 1984

Bharathiyar University, India. M.Sc., 1988

University of Madras, India. M.Phil., 1989

All India Institute of Medical Sciences, India. Ph.D., 1996

  • Postdoctoral Fellow, Stanford University, Stanford 1997-2002

Dr. Rajalingam Raja serves as the Laboratory Director, Clinical Consultant and Technical Supervisor for the UCSF Immunogenetics and Transplantation Laboratory. Dr. Raja received his Ph.D. from the Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi. Six-years of pre-doctoral studies in HLA diversity, followed by six-years of post-doctoral research in NK cell immunogenetics at Stanford, plus eighteen-years of experience in clinical histocompatibility laboratory directorship in the high volume transplant centers at UCLA and UCSF have shaped Dr. Raja into one of the uniquely experienced investigators committed to the fields of histocompatibility, immunogenetics and transplant immunology.

  Confired By    
  • Prof. NK Mehra Oration Award 2016
  • Indian Society for Histocompatibility and Immunogenetics (ISHI)
  • 2016
  • Certificate of Qualification, Histocompatibility Laboratory Director
  • New York State Department of Health
  • 2012
  • Histocompatibility Laboratory Director
  • Department of Public Health, State of California
  • 2009
  • Clinical Immunology Training Award
  • 1996
  • Clinical Immunology Training Award
  • Federal of Immunological Societies of Asia-Oceania/International Union of Immunological Societies
  • 1996
  • Shakuntala Amir Chand prize for the best Ph.D. thesis in Biomedical Sciences in India
  • Indian Council of Medical Research (ICMR)
  • 1996
  • University First Rank in post-graduation (M.Sc.: Zoology, Biochemicstry, Molecular Biology)
  • Bharathiyar University, Coimbatore, India
  • 1988
  • Natural killer (NK) have been implicated in control and clearance of malignant and virally infected cells, regulation of adaptive immune responses, rejection of bone marrow transplants, autoimmunity and the maintenance of pregnancy. Human NK cells largely use a family of Human Leukocyte Antigen (HLA)-specific Killer cell Immunoglobulin-like Receptors (KIR) to recognize and respond to the unhealthy target cells. KIR and HLA loci are both polygenic and substantially polymorphic, and they map to distinct human chromosomes (Chromosomes 19 and 6, respectively).

    KIR and HLA gene families segregate independently, yielding many individuals who express KIR receptors for which they lack HLA class I ligands, and vice versa, thus creating human diversity in the number and type of KIR-HLA inherited gene pairs, which potentially could influence the health and disease status of a given individual. The overall goal of our research is to understand the diversity of KIR receptors, HLA ligands, and KIR-HLA gene combinations in populations and their relevance in human health and disease.

    Data provided by UCSF Profiles, powered by CTSI
    1. Diego VP, Luu BW, Hofmann M, Dinh LV, Almeida M, Powell JS, Rajalingam R, Peralta JM, Kumar S, Curran JE, Sauna ZE, Kellerman R, Park Y, Key NS, Escobar MA, Huynh H, Verhagen AM, Williams-Blangero S, Lehmann PV, Maraskovsky E, Blangero J, Howard TE. Quantitative HLA-class-II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. J Thromb Haemost. 2020 01; 18(1):201-216. View in PubMed
    2. Roll GR, Webber AB, Gae DH, Laszik Z, Tavakol M, Mayen L, Cunniffe K, Syed S, Hirose R, Freise C, Feng S, Roberts JP, Ascher NL, Stock PG, Rajalingam R. A Virtual Crossmatch-based Strategy Facilitates Sharing of Deceased Donor Kidneys for Highly Sensitized Recipients. Transplantation. 2020 06; 104(6):1239-1245. View in PubMed
    3. Gupta N, Henry RG, Kang SM, Strober J, Lim DA, Ryan T, Perry R, Farrell J, Ulman M, Rajalingam R, Gage A, Huhn SL, Barkovich AJ, Rowitch DH. Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease. Stem Cell Reports. 2019 08 13; 13(2):254-261. View in PubMed
    4. Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina M, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019 09 19; 134(12):924-934. View in PubMed
    5. Gao Y, Twigg AR, Hirose R, Roll GR, Nowacki AS, Maytin EV, Vidimos AT, Rajalingam R, Arron ST. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant. JAMA Dermatol. 2019 03 01; 155(3):307-314. View in PubMed
    6. View All Publications


    Site Directory